Rabpharma is dedicated to the research and development of first-in-class new drugs in the field of bone and joint diseases. 

Since establishment, we have built a comprehensive set of technology platforms, including PDC conjugation and high-throughput screening. 

Our first product for the treatment of osteonecrosis, RAB001, has completed Phase I clinical trials in the United States and  Phase I bridging clinical trial in China. And its Phase II clinical trial has launched in 2024.